04 · Alert System
Enforcement actions, monograph rulings, Rx-to-OTC pipeline events, and commercial signals requiring immediate consultant awareness. Red requires action, amber requires monitoring, green flags opportunity.
Last reviewed November 2026
0 red alerts activeFDA proposed removing oral phenylephrine as an OTC nasal decongestant ingredient in November 2024, after concluding it is not effective at approved doses. The comment period closed in May 2025, and the final order once expected "sometime in 2026" has not published. A separate August 2026 amendment recognized phenylephrine bitartrate in effervescent form, which does not resolve the oral question. Brand teams carrying oral phenylephrine SKUs should keep reformulation or delisting plans ready, without committing budget to a date FDA has not confirmed.
Consumer search and social signals also inform velocity rating.
Legacy OTC and supplement brands continue to market multivitamin, fiber, and protein products explicitly to GLP-1 users. Clinicians note a lack of strong controlled evidence for these products' effect on GLP-1 side effects. FTC action against a telemedicine company over GLP-1 marketing claims shows the agency applying the same standard beyond supplements. No action against a specific OTC companion brand has surfaced yet; that is a liability gap, not a cleared path.
Consumer search and social signals also inform velocity rating.
FDA's final order added bemotrizinol at up to 6 percent to the sunscreen monograph in June 2026. The prior edition expected market entry on August 9, 2026; the first branded launch, Ultra Violette Unblock Screen SPF 50 at Sephora, shipped August 31, 2026. dsm-firmenich's Parsol Shield ingredient is also reaching other formulators. Confirm the exact exclusivity clock start with counsel before advising clients on launch timing.
Consumer search and social signals also inform velocity rating.
FDA's August 2026 final monograph amendment recognizes phenylephrine bitartrate as safe and effective specifically in effervescent dosage form, alone or combined with aspirin and chlorpheniramine. Sinusitis is removed as a permitted indication in that form. This gives decongestant brands a compliant reformulation path while the broader oral-PE removal order remains unresolved.
Consumer search and social signals also inform velocity rating.
The president signed OMUFA II into law on November 12, 2025, reauthorizing monograph user fees for fiscal years 2026 through 2030. FDA's reauthorization page confirms the FY2026-2030 fee structure is in effect. Five-year funding certainty makes the streamlined monograph order pathway a durable, predictable route to market. Sponsors should budget monograph order requests into multi-year innovation planning.
Consumer search and social signals also inform velocity rating.
"The OTC claim environment rewards scientific precision. Brands with a clear evidence story are gaining ground on those relying on heritage equity alone."
Schedule a consultation →